Treatment Considerations for Lobular Breast Cancer in Postmenopausal Women

Systemic Treatment Algorithm by Clinical Scenario

The National Comprehensive Cancer Network recommends that for postmenopausal women with lobular breast cancer, treatment follows the same evidence-based algorithms as ductal carcinoma, determined primarily by lymph node status, tumor size, and hormone receptor status—not by lobular histology itself 1, 2
For ER-positive disease, the British Journal of Cancer suggests that Tamoxifen is the standard adjuvant endocrine therapy in postmenopausal women with node-positive disease 4
The National Comprehensive Cancer Network recommends that aromatase inhibitors should be used either as initial adjuvant therapy, sequential with tamoxifen, or as extended therapy after tamoxifen in postmenopausal women 1, 2
Chemotherapy is mandatory (Category 1) regardless of hormone receptor status when lymph nodes are involved, as recommended by the National Comprehensive Cancer Network 1, 2, 5
The National Comprehensive Cancer Network suggests that sequential administration is required: complete chemotherapy first, then begin endocrine therapy, as concurrent tamoxifen with chemotherapy reduces disease-free survival 1, 2, 5

The National Comprehensive Cancer Network recommends that sequential anthracycline-cyclophosphamide followed by taxane (AC-T) is the most effective adjuvant regimen for early-stage breast cancer regardless of histology, although this specific citation is from Praxis Medical Insights 5
Anthracycline- and taxane-containing regimens (4-8 cycles) are standard for node-positive disease, as suggested by the British Journal of Cancer and Praxis Medical Insights 4, 7

The National Comprehensive Cancer Network recommends that for postmenopausal women with ER-positive disease, aromatase inhibitors are preferred over tamoxifen alone 1, 2

The National Comprehensive Cancer Network recommends that chemotherapy should not be omitted in node-positive lobular cancer based solely on favorable biology (low grade, low Ki67, low RS) 1, 2, 5
The National Comprehensive Cancer Network suggests that tamoxifen alone should not be used in postmenopausal women when aromatase inhibitors are available 1, 2
The National Comprehensive Cancer Network recommends that tamoxifen should not be administered concurrently with chemotherapy; always give sequentially 1, 2, 5